Esteve Quimica S.a.

Esteve Qu&iacute;mica, S.a.

Laura Coppi

Ramón Berenguer Maimó

Jorge Medrano Rupérez

Julio Campon Pardo

Yolanda Gasanz Guillén

Marti Bartra Sanmarti

Montserrat Closa Clavo

Yolanda Gasanz Guillen

Julio Camp&oacute;n Pardo

Yolanda Gasanz Guill&eacute;n

New solid forms of the active ingredient magnesium salt of S-omeprazole, obtainable by a preparation process including: a) crystallizing a magnesium salt of S-omeprazole from a solution of a magnesium salt of S-omeprazole in a solvent system that includes a mixture of methanol/water with an amount of water equal to or greater than about 0.01 ml/g of the magnesium salt of S-omeprazole starting material; b) isolating the magnesium salt of S-omeprazole that appears in the prior operation; c) separating the free organic solvent from the magnesium salt of S-omeprazole obtained or, alternatively, separating both the free solvent and the solvation solvent. The new solid forms are obtained by a reproducible and robust process, with high yield and elevated optical purity, which is useful for the preparation of pharmaceutical products that contain said active ingredient.

Solid forms of the magnesium salt of S-omeprazole and processes for their preparation

Process for the preparation of optically active derivatives of 2-(2-piridylmethylsulfinyl)-benzimidazole, or salts thereof, by resolution of the corresponding racemic derivatives of 2-(2-piridylmethylsulfinyl)-benzimidazole. The resolution is performed through the formation of inclusion complexes with (S)-(&#x2212;) or (R)-(+)-[1,1'-Binaphthalene]-2,2&#x2032;-diol in the presence of an amine, followed by the break of the inclusion complex by treatment with an hydroxide of an alkaline metal. The enantiomer of the derivative of 2-(2-piridylmethylsulfinyl)-benzimidazole may be obtained by extractions at a particular pH with a suitable organic solvent. The process allows to perform the resolution with high yields and high optical purity, without using neither toxic solvents nor chromatography.

Process for the preparation of optically active derivatives of 2-(2-pyridylmethylsulfinyl)-benzimidazole via inclusion complex with 1,1'-binaphthalene-2,2&#x2032;diol

The invention relates to the new crystalline forms II, III and V of meloxicam; to the processes for obtaining the crystalline forms I, II, III and V; and, finally, to the interconversion processes of the forms II, III, IV and V into the form I.

Crystalline forms of meloxicam and processes for their preparation and interconversion

Process for preparing purified citalopram or one of its salts that comprises the purification of citalopram by selective extractions of citalopram or of its impurities with organic solvents and water under specific conditions of pH and temperature. The crude citalopram can be prepared by a process that comprises reacting 1-&lsqb;3-(dimethylamine)propyl&rsqb;-1-(4-fluorophenyl)-1,3-dihydro-5-bromoisobenzofuran with copper cyanide.

Process for preparing citalopram

Intermediate for the synthesis of amlodipine, a process for the preparation thereof and corresponding use

The present invention relates to a procedure for the oxidation of a thioether group to a sulfoxide group, with aqueous sodium percarbonate in the presence of a molybdenum salt as a catalyst. The procedure is of application to oxidize the thioether group of a compound (I), where R is a C -C alkyl, a halogenated C -C alkyl, or &mdash;(CH ) &mdash;OR , where n is an integer between 1 and 6 and R is H or a C -C alkyl; R , R , R , R , R and R , independently form each other represent H, a C -C alkyl, or C -C alkoxy; and R is H, a C -C alkyl, a C -C alkoxy or a C -C fluorinated alkoxy, in order to obtain the sulfinyl derivative (II).

Growing community of inventors

Barcelona, Spain

Laura Coppi